Cargando…
Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with diabetes. The mechanism underlying the beneficial effect of SGLT2 inhibitors i...
Autores principales: | Durante, William, Behnammanesh, Ghazaleh, Peyton, Kelly J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396183/ https://www.ncbi.nlm.nih.gov/pubmed/34445519 http://dx.doi.org/10.3390/ijms22168786 |
Ejemplares similares
-
Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2020) -
Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1
por: Peyton, Kelly J., et al.
Publicado: (2022) -
Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
por: Kourtidou, Christodoula, et al.
Publicado: (2023) -
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2019) -
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)